Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393013 · ClinicalTrials.gov registry record · Phase 1
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
A Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Kezar Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT03393013 is a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis that has completed, run by Kezar Life Sciences. The registered enrollment target is 69 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03393013, a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, has completed, sponsored by Kezar Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
Conditions Studied
Interventions
- DRUG KZR-616
Study Locations (20)
Florida
- SouthCoast Research Center, Inc. - Miami
- Hope Clinical Trials, Inc. - Miami
- Omega Research Maitland - Orlando
- Arthritis Center, Inc - Palm Harbor
- Advent Health Medical Group - Tampa
New York
- Northwell Health - Great Neck
- NYU Langone Orthopedic Center - Seligman Center for Advanced Therapeutics - New York
- University of Rochester Medical Center - Rochester
Texas
- MedResearch, Inc. - El Paso
- Accurate Clinical Research, Inc. - Houston
- Accurate Clinical Management, LLC - Houston
California
- Academic Medical Research Institute - Los Angeles
- Inland Rheumatology Clinical Trials, Inc. - Upland
Victoria
- Monash Health - Clayton
- The Royal Melbourne Hospital - Parkville
Iowa
- University of Iowa - Iowa City
Ohio
- The Ohio State University Wexner Medical Center - Columbus
South Carolina
- SC Nephrology & Hypertension Center, Inc. - Orangeburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2022-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393013
The ClinicalTrials.gov registry entry for NCT03393013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (82% lower). The listed sponsor is Kezar Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which KZR-616 is the first listed.
NCT03393013 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT03393013 about?
NCT03393013 is a clinical study titled "A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis". This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
What is the current status of trial NCT03393013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2018-02-20. Estimated completion is 2022-08-04.
What conditions does trial NCT03393013 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus Nephritis.
What interventions are being tested in trial NCT03393013?
The interventions under investigation include: KZR-616 (DRUG).
Who is sponsoring clinical trial NCT03393013?
This trial is sponsored by Kezar Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03393013 being conducted?
This trial has 20 study locations across California, Florida, Iowa, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.